An audit between April 2020 and June 2024 showed that no participant had a heart attack or stroke.
Since April 2020 we have conducted a clinical audit on the efficacy of the Polypill we use to prevent heart attacks and strokes. During the period of the audit between April 2020 and June 2024 no participant had a heart attack or stroke. This compares with 3.6 expected* among participants in the Polypill Prevention Programme had they not been taking the Polypill.
The observation that no participant had a heart attack or stroke when 3.6 would be expected is statistically significant. While participants are likely to be a healthier group than people in the general population the audit results offer supporting evidence of the efficacy of the programme.
*The expected is based on national incidence rates and takes account of the average background use of blood pressure and cholesterol lowering medication as described in Wald, N.J. and Morris, J.K., 2014. Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example. European journal of epidemiology, 29, pp.605-612..